FUTURE BLOOD SCREENING ASSAY- ULTRIO 2 ADDENDUM AMENDING AGREEMENT ENTERED INTO AS OF JUNE 11, 1998 BY AND BETWEEN GEN-PROBE INCORPORATED AND NOVARTIS VACCINES & DIAGNOSTICS, INC.Future Blood Screening Assay - Ultrio 2 Addendum • February 25th, 2009 • Gen Probe Inc • Surgical & medical instruments & apparatus
This Future Blood Screening Assay — Ultrio 2 Addendum (the “Ultrio 2 Addendum”) is entered into, effective as of October 1, 2008 (the “Addendum Effective Date”) pursuant to and amending that certain Agreement entered into as of June 11, 1998 (the “Agreement”) by and between Gen-Probe Incorporated, a Delaware corporation (“Gen-Probe”) with a principal place of business at 10210 Genetic Center Drive, San Diego CA 92121, and Novartis Vaccines & Diagnostics, Inc., a Delaware corporation (“Novartis”; and collectively with Gen-Probe, the “parties”) with a place of business at 4560 Horton Street, Emeryville, CA 94608.
